🔑 It is highly variable (ranging from 11-100%) even in those without heart failure
🔑 This variability is both between patients and within the same patient
12/ Given that there is little diuretic or natriuretic effect below a given plasma concentration (the “threshold”), it could be that reduced peak absorption results in less reliable natriuresis.
16/ Clearly, many patients can achieve natriuresis with oral furosemide, even when decompensated.
But others have absorption issues, whether from delayed gastric emptying, "gut edema", or something else.
Here, as with much in medicine, the exceptions drive our practice.
17/17 CONCLUSIONS
⚡️Though furosemide absorption may be delayed during decompensated heart failure
⚡️Total absorption appears less affected
⚡️Delayed absorption may be related to delayed gastric emptying
You are seeing a patient recently diagnosed with heart failure and started on GDMT. You notice that their hemoglobin (HGB) has increased (12 → 13 g/dL) in the intervening weeks.
🤔Which medication is the likely cause of this increase in HGB?
2/12 - An Answer
Empagliflozin
💡All SGLT2 inhibitors have been associated with an increase in hematocrit/hemoglobin soon after initiation.
The average increase is 2.3% in hematocrit and 0.6 g/dL in hemoglobin.
The effect of SGLT2 inhibitors on HCT/HGB has been noted since the very first randomized control trial of dapagliflozin, published in 2010.
Initially, investigators assumed this was related to the diuretic effect of these drugs (i.e., a reduction in plasma volume led to an increase in HCT/HGB).
3/ The mutation in the Factor V gene conferring resistance to activated protein C was detailed the following year by a group in Leiden, The Netherlands.